A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Conditions
- Atopic Dermatitis
- Interventions
- Registration Number
- NCT06389136
- Lead Sponsor
- AbbVie
- Brief Summary
Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not be enough to control the AD in trial participants who require systemic anti-inflammatory treatment. This study aims to provide data on the efficacy and safety of upadacitinib at different doses in adult participants with moderate to severe AD.
Upadacitinib is an approved drug for the treatment of moderate to severe atopic dermatitis (AD). This study is conducted in 2 periods. During Period 1, participants are randomly assigned into 1 of 2 groups called treatment arms to receive upadacitinib Dose A or dupilumab Dose A. Based on the participants response to upadacitinib Dose A, they may have their dose increased to upadacitinib Dose B after 2 weeks. In Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema Area and Severity Index (EASI) response. Approximately 300 adult participants ages 18 to 64 with moderate to severe AD who are current users of dupilumab and had a history of inadequate response to dupilumab will be enrolled at up to 94 sites worldwide.
The study is comprised of a 35-day Screening Period, an 8-week Open-Label Period 1 and a 24-week Open-Label Period 2 for participants that completed Period 1. Participants will receive upadacitinib oral tablets once daily or dupilumab subcutaneous (SC) injection every other week for 32 weeks and followed for 30 days.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 300
- Participant meets all the following disease activity criteria at Baseline Visit:
- Eczema Area and Severity Index (EASI) score >= 12;
- validated Investigator´s Global Assessment for AD (vIGA-AD) score >= 3;
- Body surface area (BSA) involvement of >= 10% in a majority of subjects (>= 50% of the overall study population)
- Baseline weekly average of daily Worst Pruritus-Numerical Rating Scale (WP-NRS) >= 4. Note: The Baseline weekly average of daily WP-NRS will be calculated from the 7 consecutive days immediately preceding the Baseline Visit. A minimum of 4 daily scores out of the 7 days is needed.
- Inadequate response to dupilumab treatment after at least 4 months of current use.
- Particpant has applied a topical emollient (an additive-free, bland emollient moisturizer) twice daily for at least 7 days before the Baseline Visit and for the duration of the study. Note: Subject may use prescription moisturizers or moisturizers containing ceramide, urea, filaggrin degradation products or hyaluronic acid if such moisturizers were initiated before the Screening visit.
-
Meeting any of the following conditions at Baseline:
- Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline Visit or would interfere with assessment of AD lesions;
- Two or more past episodes of herpes zoster, or one or more episodes of disseminated herpes zoster;
- One or more past episodes of disseminated herpes simplex (including eczema herpeticum);
- HIV infection defined as confirmed positive anti- HIV Ab test;
- Active TB or meet TB exclusionary parameters (specific requirements for TB testing are provided in the operations manual);
- For Japan: Positive result of beta-D-glucan (screening for Pneumocystis jirovecii infection) or two consecutive indeterminate results of beta-D-glucan during the Screening Period;
- Active infection(s) requiring treatment with intravenous anti-infectives within 30 days, or oral/intramuscular anti-infectives within 14 days prior to the Baseline Visit;
- Chronic recurring infection and/or active viral infection that, based on the investigator's clinical assessment, makes the subject an unsuitable candidate for the study;
- COVID-19 infection: In subjects who tested positive for COVID-19, at least 5 days must have passed between a COVID-19 positive test result and the Baseline visit of asymptomatic subjects. Subjects with mild/moderate COVID-19 infection can be enrolled if fever is resolved without use of antipyretics for 24 hours and other symptoms improved, or if 5 days have passed since the COVID-19 positive test result (whichever comes last). Subjects may be rescreened if deemed appropriate by the investigator based upon the subject's health status.
-
Chronic AD with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria.- Participants with current or past history of infection including, Evidence of Hepatitis B virus (HBV) or Hepatitis C virus (HCV)
-
At Baseline any of the following medical diseases or disorders:
- Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting, (note: include the following only for new protocols) and aorto-coronary bypass surgery or venous thromboembolism;
- Any unstable clinical condition which, in the opinion of the investigator would put the subject at risk by participating in the protocol;
- Diagnosed active parasitic infection, suspected or high risk of parasitic infection unless clinical (and if necessary) laboratory assessment have ruled out active infection before randomization;
- History of an organ transplant which requires continued immunosuppression;
- History of an allergic reaction or significant sensitivity to constituents of the study drug (and its excipients) and/or other products in the same class;
- History of GI perforation (other than due to appendicitis or mechanical injury), diverticulitis, or significantly increased risk for GI perforation per investigator judgment;
- Conditions that could interfere with drug absorption including but not limited to short bowel syndrome or gastric bypass surgery; subjects with a history of gastric banding/segmentation are not excluded;
- History of malignancy except for successfully treated non-melanoma skin cancer (NMSC) or localized carcinoma in situ of the cervix;
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SEQUENTIAL
- Arm && Interventions
Group Intervention Description Period 2 Open Label: Dupilumab ≥ EASI 75 Response Dupilumab Dose A Participants that were receiving Dupilumab Dose A and completed Period 1, will continue to receive Dupilumab Dose A SC injection in Period 2 with a clinical response of ≥ EASI 75 at Week 8 Period 1: Upadacitinib Open Label Treatment Upadacitinib Dose A Participants randomly assigned to receive Upadacitinib Dose A tablet once per day. Based on clinical response, participants randomized to Upadacitinib Dose A will have their dose increased to Upadacitinib Dose B starting at Week 2. Period 1: Upadacitinib Open Label Treatment Upadacitinib Dose B Participants randomly assigned to receive Upadacitinib Dose A tablet once per day. Based on clinical response, participants randomized to Upadacitinib Dose A will have their dose increased to Upadacitinib Dose B starting at Week 2. Period 1: Dupilumab Open Label Treatment Dupilumab Dose A Participants randomly assigned to receive Dupilumab Dose A SC injection once every other week for 8 weeks. Period 2 Open Label: Upadacitinib < EASI 75 response Upadacitinib Dose B Participants that were receiving Upadacitinib Dose A or Dose B and completed Period 1, will be allocated or continue to receive oral doses of Upadacitinib Dose B in Period 2 with a clinical response of \< EASI 75 at Week 8 Period 2 Open Label: Upadacitinib ≥ EASI 75 Response Upadacitinib Dose A Participants that were receiving Upadacitinib Dose A or Dose B and completed Period 1, will continue to receive the same oral doses of Upadacitinib in Period 2 with a clinical response of ≥ EASI 75 at Week 8 Period 2 Open Label: Upadacitinib ≥ EASI 75 Response Upadacitinib Dose B Participants that were receiving Upadacitinib Dose A or Dose B and completed Period 1, will continue to receive the same oral doses of Upadacitinib in Period 2 with a clinical response of ≥ EASI 75 at Week 8 Period 2 Open Label Period: Dupilumab < EASI 75 Response Upadacitinib Dose A Participants that were receiving Dupilumab Dose A and completed Period 1, will receive oral doses of Upadacitinib Dose A in Period 2 with a clinical response of \< EASI 75 at Week 8
- Primary Outcome Measures
Name Time Method Participants who simultaneous achieve at least a 90% reduction in Eczema Area and Severity Index from Baseline (EASI 90) and Worst Pruritus Numerical Rating Scale of 0 or 1 (WP-NRS 0/1) At Week 8 The EASI is a validated measure used to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points.
Worst Pruritus NRS (WP-NRS) is a validated single self-reported measure where patients rate the worst level of itching they have experienced over the past 24 hours on a scale from 0 (no itching) to 10 (worst itching imaginable)
- Secondary Outcome Measures
Name Time Method Percentage of participants who achieve EASI 90 At Week 8 The EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. Four AD disease characteristics (erythema, thickness \[induration, papulation, edema\], scratching \[excoriation\], and lichenification) are each assessed for severity by the investigator on a scale of "0" (absent) through "3" (severe). In addition, the area of AD involvement is assessed as a percentage by body area of head, trunk (including the genital area), upper extremities, and lower extremities (including the buttocks), and converted to a score of 0 to 6. In each body region, the area is expressed as 0, 1 (1% to 9%), 2 (10% to 29%), 3 (30% to 49%), 4 (50% to 69%), 5 (70% to 89%), or 6 (90% to 100%). The EASI score ranges from 0-72 points with an MCID of 6.6 points. Published score bands: clear (0), almost clear (0.1-1.0), mild AD (1.1-7.0), moderate AD (7.1-21.0), severe AD (21.1-50.0), very severe AD (50.1-72.0).
Percentage of participants achieving worst pruritus numerical rating scale (WP-NRS) 0/1 At Week 4 Worst Pruritus NRS (WP-NRS) is a validated single self-reported measure where patients rate the worst level of itching they have experienced over the past 24 hours on a scale from 0 (no itching) to 10 (worst itching imaginable)
Trial Locations
- Locations (94)
Apex Clinical Trials /ID# 263747
🇺🇸Brandon, Florida, United States
Skin Care Research - Tampa /ID# 263750
🇺🇸Tampa, Florida, United States
Clinical Trials Institute - Northwest Arkansas /ID# 267290
🇺🇸Fayetteville, Arkansas, United States
Joseph Raoof Md,Inc /Id# 263849
🇺🇸Encino, California, United States
Allergy & Asthma Associates of Southern California - Mission Viejo /ID# 266574
🇺🇸Mission Viejo, California, United States
Dermatologist Medical Group of North County- Profound Research /ID# 266512
🇺🇸Oceanside, California, United States
Stanford University School of Medicine - Redwood City /ID# 263776
🇺🇸Redwood City, California, United States
Integrative Skin Science and Research /ID# 264537
🇺🇸Sacramento, California, United States
West Dermatology La Jolla /ID# 265014
🇺🇸San Diego, California, United States
Clinical Trials Research Institute /ID# 263846
🇺🇸Thousand Oaks, California, United States
Yale University School of Medicine /ID# 263836
🇺🇸New Haven, Connecticut, United States
Clearlyderm Dermatology - West Boca /ID# 264923
🇺🇸Boca Raton, Florida, United States
Skin Care Research Boca Raton /ID# 263733
🇺🇸Boca Raton, Florida, United States
TrueBlue Clinical Research /ID# 265037
🇺🇸Brandon, Florida, United States
Life Clinical Trials /ID# 267195
🇺🇸Coral Springs, Florida, United States
Revival Research - Doral /ID# 263541
🇺🇸Doral, Florida, United States
Skin Care Research - Hollywood /ID# 263739
🇺🇸Hollywood, Florida, United States
Solutions Through Advanced Research /ID# 263392
🇺🇸Jacksonville, Florida, United States
GSI Clinical Research, LLC /ID# 263760
🇺🇸Margate, Florida, United States
Quality Research of South Florida /ID# 266496
🇺🇸Miami Lakes, Florida, United States
Research Associates of South Florida /ID# 267291
🇺🇸Miami, Florida, United States
International Dermatology Research /ID# 264961
🇺🇸Miami, Florida, United States
Sullivan Dermatology /ID# 263537
🇺🇸Miami, Florida, United States
Lenus Research and Medical Group /ID# 263779
🇺🇸Miami, Florida, United States
Global Clinical Professionals (GCP) /ID# 266474
🇺🇸Saint Petersburg, Florida, United States
Alliance Clinical Research of Tampa /ID# 264531
🇺🇸Tampa, Florida, United States
Centricity Research Columbus Dermatology /ID# 266529
🇺🇸Columbus, Georgia, United States
Cleaver Medical Group Dermatology /ID# 263788
🇺🇸Dawsonville, Georgia, United States
Georgia Skin & Cancer Clinic /ID# 267199
🇺🇸Savannah, Georgia, United States
Treasure Valley Medical Research /ID# 263738
🇺🇸Boise, Idaho, United States
Northwestern University Feinberg School of Medicine /ID# 264983
🇺🇸Chicago, Illinois, United States
DeNova Research /ID# 264513
🇺🇸Chicago, Illinois, United States
Dawes Fretzin, LLC /ID# 264534
🇺🇸Indianapolis, Indiana, United States
Options Research Group /ID# 264564
🇺🇸West Lafayette, Indiana, United States
Dermatology Specialists Research (DS Research) - Kentucky /ID# 263388
🇺🇸Louisville, Kentucky, United States
Velocity Clinical Research at The Dermatology Clinic - Baton Rouge /ID# 267169
🇺🇸Baton Rouge, Louisiana, United States
Boston Specialists /ID# 265810
🇺🇸Boston, Massachusetts, United States
Beth Israel Deaconess Medical Center /ID# 263703
🇺🇸Boston, Massachusetts, United States
Beacon Clinical Research /ID# 263843
🇺🇸Quincy, Massachusetts, United States
Great Lakes Research Group - Bay City /ID# 263535
🇺🇸Bay City, Michigan, United States
Henry Ford Medical Center - New Center One /ID# 263522
🇺🇸Detroit, Michigan, United States
Onyx Clinical Research - Flint - South Linden Road /ID# 267773
🇺🇸Flint, Michigan, United States
MediSearch Clinical Trials /ID# 263579
🇺🇸Saint Joseph, Missouri, United States
Physician Research Collaboration, LLC /ID# 263583
🇺🇸Lincoln, Nebraska, United States
Skin Specialists /ID# 263345
🇺🇸Omaha, Nebraska, United States
Skin Cancer and Dermatology Institute - Reno /ID# 263771
🇺🇸Reno, Nevada, United States
Dartmouth Hitchcock Medical Center - Old Etna Road /ID# 263840
🇺🇸Lebanon, New Hampshire, United States
Forest Hills Dermatology Group @ Union Turnpike /ID# 263755
🇺🇸Kew Gardens, New York, United States
Equity Medical, LLC /ID# 265814
🇺🇸New York, New York, United States
Piedmont Plastic Surgery and Dermatology /ID# 266545
🇺🇸Huntersville, North Carolina, United States
Vital Prospects Clinical Research Institute - Tulsa /ID# 263645
🇺🇸Tulsa, Oklahoma, United States
Oregon Health and Science University /ID# 263736
🇺🇸Portland, Oregon, United States
Dermatology Partners /ID# 264972
🇺🇸Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center /ID# 264526
🇺🇸Pittsburgh, Pennsylvania, United States
Dermatology Associates of Plymouth Meeting /ID# 267286
🇺🇸Plymouth Meeting, Pennsylvania, United States
Medical University of South Carolina /ID# 263655
🇺🇸Charleston, South Carolina, United States
ADCS - Spartanburg /ID# 267185
🇺🇸Spartanburg, South Carolina, United States
Arlington Research Center, Inc /ID# 263665
🇺🇸Arlington, Texas, United States
Orion Clinical Research /ID# 263658
🇺🇸Austin, Texas, United States
Bellaire Dermatology Associates /ID# 263794
🇺🇸Bellaire, Texas, United States
Studies in Dermatology LLC /ID# 263335
🇺🇸Cypress, Texas, United States
Dermatology Treatment and Research Center /ID# 265812
🇺🇸Dallas, Texas, United States
Modern Research Associates /ID# 263852
🇺🇸Dallas, Texas, United States
The Dermatology Institute of South Texas /ID# 267332
🇺🇸McAllen, Texas, United States
Texas Dermatology Research Center /ID# 264528
🇺🇸Plano, Texas, United States
Stride Clinical Research /ID# 267331
🇺🇸Sugar Land, Texas, United States
The Woodlands Dermatology Associates /ID# 266547
🇺🇸The Woodlands, Texas, United States
Dermatology Associates of Tyler /ID# 264980
🇺🇸Tyler, Texas, United States
West Virginia Research Institute - Morgantown /ID# 264930
🇺🇸Morgantown, West Virginia, United States
Dermatology Research Institute - Blackfoot Trail /ID# 270450
🇨🇦Calgary, Alberta, Canada
Centre de Recherche Saint-Louis /ID# 271083
🇨🇦Québec, Quebec, Canada
Centro de Inmunología y Genética CIGE SAS /ID# 266200
🇨🇴Medellín, Antioquia, Colombia
Centro Integral de Reumatología del Caribe SAS - Circaribe SAS /ID# 265088
🇨🇴Barranquilla, Atlantico, Colombia
Centro de Investigacion en Reumatologia y especialidades Medicas S.A.S- CIREEM /ID# 265092
🇨🇴Bogotá, Cundinamarca, Colombia
Unidad Integral de Endocrinologia (UNIENDO) /ID# 266970
🇨🇴Bogotá, Cundinamarca, Colombia
Ichinomiya Municipal Hospital /ID# 265068
🇯🇵Ichinomiya, Aichi, Japan
Takeoka Dermatology Clinic /ID# 264055
🇯🇵Marugame, Kagawa, Japan
Kawasaki Medical School Hospital /ID# 266164
🇯🇵Kurashiki, Okayama, Japan
Dokkyo Medical University Hospital /ID# 265431
🇯🇵Mibu, Tochigi, Japan
Tachikawa Dermatology Clinic /ID# 271912
🇯🇵Tachikawa-shi, Tokyo, Japan
Katahira Dermatology Urology Clinic /ID# 264403
🇯🇵Kagoshima, Japan
NTT Medical Center Tokyo /ID# 265104
🇯🇵Tokyo, Japan
Teikyo University Hospital /ID# 265126
🇯🇵Tokyo, Japan
Korea University Ansan Hospital /ID# 263330
🇰🇷Ansan-si, Gyeonggido, Korea, Republic of
Soon Chun Hyang University Hospital Bucheon /ID# 263331
🇰🇷Bucheon-si, Gyeonggido, Korea, Republic of
Ajou University Hospital /ID# 263328
🇰🇷Suwon-si, Gyeonggido, Korea, Republic of
Seoul National University Hospital /ID# 263329
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Konkuk University Medical Center /ID# 263327
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
SCB Research Center /ID# 263217
🇵🇷Bayamon, Puerto Rico
Private Practice - Dr. Samuel Sanchez /ID# 263199
🇵🇷Caguas, Puerto Rico
Private Practice - Dr. Alma Cruz /ID# 263216
🇵🇷Carolina, Puerto Rico
Clinical Research Puerto Rico /ID# 263197
🇵🇷San Juan, Puerto Rico
GCM Medical Group, PSC /ID# 263218
🇵🇷San Juan, Puerto Rico
Caribbean Medical Research Center /ID# 267163
🇵🇷San Juan, Puerto Rico